These differences did not reach statistical significance, likely due to the limited number of patients that completed the questionnaires at subsequent time points.
← all excerpts
Reply letter to comments on: Impact of age and sex on the efficacy and safety of ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line oxaliplatin-based chemotherapy: a subgroup analysis of the ARMANI phase III trial.
1
—
—